Baricitinib
- PDF / 169,688 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 32 Downloads / 164 Views
1
Baricitinib Molluscum contagiosum: case report A 31-year-old man developed molluscum contagiosum infection while receiving baricitinib for atopic dermatitis. The man had a medical history of childhood onset atopic dermatitis and was a part of phase III clinical trial of baricitinib. He had been receiving baritinib, either 2mg or 4mg [route and frequency not stated], and within 2 weeks of the therapy, he started developing multiple flesh-coloured papules, measuring 2–3mm diameter, on his trunk. The eruption spread over his bilateral thighs and the neck during the following 4 weeks; the lesions appeared with umbilication. He was diagnosed with molluscum contagiosum. The man was treated with combination of salicylic acid and lactic acid for 8 weeks and was applied topical preparation containing cantharidin, salicylic acid and podophyllin subsequently. However, the lesions did not resolve. Therefore, he opted out of the trial at week-24. Four weeks after discontinuation of baricitinib, there was significant reduction in the molluscum lesions. A few lesions persisted on his trunk, as well in areas of the groin and neck. Author comment: "Molluscum contagiosum should be recognised as a potential complication of JAK inhibitors, particularly in predisposed patients such as those with impaired skin barrier function." Wong GN, et al. A case of widespread molluscum contagiosum caused by baricitinib, a Janus kinase inhibitor. Australasian Journal of Dermatology 60: e334-e335, No. 4, Nov 2019. Available from: URL: http://doi.org/10.1111/ 803439939 ajd.13059 - Australia
0114-9954/19/1783-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Dec 2019 No. 1783
Data Loading...
